NO20021959L - Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer - Google Patents

Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer

Info

Publication number
NO20021959L
NO20021959L NO20021959A NO20021959A NO20021959L NO 20021959 L NO20021959 L NO 20021959L NO 20021959 A NO20021959 A NO 20021959A NO 20021959 A NO20021959 A NO 20021959A NO 20021959 L NO20021959 L NO 20021959L
Authority
NO
Norway
Prior art keywords
tetrahydrotiopyranephthalazinone
derivatives
pde4 inhibitors
pde4
inhibitors
Prior art date
Application number
NO20021959A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021959D0 (no
Inventor
Armin Hatzelmann
Daniela Bundschuh
Hans-Peter Kley
Geert Jan Sterk
Ivonne Johanna Van Der Laan
Hendrik Timmerman
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of NO20021959D0 publication Critical patent/NO20021959D0/no
Publication of NO20021959L publication Critical patent/NO20021959L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20021959A 1999-10-25 2002-04-25 Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer NO20021959L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99121243 1999-10-25
US20395000P 2000-05-12 2000-05-12
PCT/EP2000/010445 WO2001030777A1 (en) 1999-10-25 2000-10-24 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors

Publications (2)

Publication Number Publication Date
NO20021959D0 NO20021959D0 (no) 2002-04-25
NO20021959L true NO20021959L (no) 2002-05-29

Family

ID=26153155

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021959A NO20021959L (no) 1999-10-25 2002-04-25 Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer

Country Status (20)

Country Link
US (2) US6544993B1 (es)
EP (1) EP1244654A1 (es)
JP (1) JP2003512466A (es)
KR (1) KR20020043238A (es)
CN (1) CN1146562C (es)
AU (1) AU781137B2 (es)
BR (1) BR0014990A (es)
CA (1) CA2388119A1 (es)
CZ (1) CZ20021457A3 (es)
EA (1) EA005856B1 (es)
HK (1) HK1047276A1 (es)
HR (1) HRP20020350A2 (es)
HU (1) HUP0203487A2 (es)
IL (1) IL148807A0 (es)
MX (1) MXPA02003581A (es)
NO (1) NO20021959L (es)
PL (1) PL354979A1 (es)
SK (1) SK7232002A3 (es)
TR (1) TR200201128T2 (es)
WO (1) WO2001030777A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354979A1 (en) * 1999-10-25 2004-03-22 Altana Pharma Ag Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
NZ527424A (en) * 2001-02-15 2005-02-25 Altana Pharma Ag Phthalayinone-piperidino-derivatives as PDE4 inhibitors
CN1503792A (zh) 2001-04-25 2004-06-09 ��̹��ҽҩ��˾ 新的酞嗪酮
NZ529363A (en) * 2001-04-25 2005-08-26 Altana Pharma Ag Novel Piperazino-derivatives
TWI347845B (en) * 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
EP1542987A1 (en) * 2002-08-10 2005-06-22 ALTANA Pharma AG Piperidine-n-oxide-derivatives
CA2494650A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
AU2003260376A1 (en) * 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
AU2003255376A1 (en) * 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
AU2004204355B2 (en) * 2003-01-14 2009-12-17 Nycomed Gmbh PDE4 inhibitors for the treatment of neoplasms of lymphoid cells
EP1716123A1 (en) * 2004-02-04 2006-11-02 Altana Pharma AG Pyridazinone derivatives and their use as pde4 inhibitors
WO2005075456A1 (en) 2004-02-04 2005-08-18 Altana Pharma Ag 2-(piperidin-4-yl) -4, 5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
SG182194A1 (en) * 2004-03-03 2012-07-30 Nycomed Gmbh Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors
EP2651417B1 (en) * 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CA2906008C (en) 2013-03-13 2019-07-09 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9204808D0 (en) * 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
AU673569B2 (en) 1992-12-02 1996-11-14 Pfizer Inc. Catechol diethers as selective PDE-IV inhibitors
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
AU735934B2 (en) 1997-01-15 2001-07-19 Altana Pharma Ag Phthalazinones
AU753576B2 (en) 1997-12-15 2002-10-24 Altana Pharma Ag Dihydrobenzofurans
WO1999031071A1 (en) 1997-12-15 1999-06-24 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
AU3328499A (en) 1998-03-14 1999-10-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone pde iii/iv inhibitors
PL354979A1 (en) * 1999-10-25 2004-03-22 Altana Pharma Ag Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors

Also Published As

Publication number Publication date
MXPA02003581A (es) 2002-10-23
AU781137B2 (en) 2005-05-05
AU1515101A (en) 2001-05-08
US6544993B1 (en) 2003-04-08
SK7232002A3 (en) 2002-09-10
PL354979A1 (en) 2004-03-22
CN1382137A (zh) 2002-11-27
NO20021959D0 (no) 2002-04-25
HRP20020350A2 (en) 2004-02-29
KR20020043238A (ko) 2002-06-08
EA005856B1 (ru) 2005-06-30
JP2003512466A (ja) 2003-04-02
EA200200381A1 (ru) 2002-10-31
HK1047276A1 (zh) 2003-02-14
CN1146562C (zh) 2004-04-21
BR0014990A (pt) 2002-06-18
CZ20021457A3 (cs) 2002-07-17
US20030166655A1 (en) 2003-09-04
EP1244654A1 (en) 2002-10-02
WO2001030777A1 (en) 2001-05-03
IL148807A0 (en) 2002-09-12
HUP0203487A2 (hu) 2003-02-28
US6846821B2 (en) 2005-01-25
CA2388119A1 (en) 2001-05-03
TR200201128T2 (tr) 2002-08-21

Similar Documents

Publication Publication Date Title
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20021239L (no) Pteridinoner som kinase-inhibitorer
NO20030867L (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
NO20015065D0 (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20030055L (no) Colchinolderivater som angiogenese inhibitorer
NO20014642D0 (no) Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer
NO20021329D0 (no) Kinaseinhibitorer som terapeutiske midler
DK1289985T3 (da) Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer
NO20043793L (no) Nikotinamidderivater anvendelige som PDE4 inhibitorer
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
DE60002193T2 (de) Metalloprotease inhibitoren
NO20033618D0 (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
NO20025811D0 (no) Forbindelser som er effektive som beta-2-adrenoreseptor- anonister så vel som PDE4-inhibitorer
DK1226143T3 (da) Imidazopyridinderivater som phosphodiesterase VII-inhibitorer
NO20021407L (no) Bifenylderivater anvendt som NHE-3-inhibitorer
DK1183251T3 (da) Indolylpiperidinderivater som antihistamin- og antiallergimidler
NO20021959D0 (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20014243L (no) Dihetero-substituerte metalloproteaseinhibitorer
NO20023001D0 (no) Substituerte piperazinderivater som MTP inhibitorer
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren
NO20020592D0 (no) Fluorenderivater som integrininhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application